Last reviewed · How we verify

NCT05303233: TIPACK

IPACK or Selective Tibial Nerve Block for ACL Reconstruction With an Adductor Canal Block

Completed NA Last updated 8 August 2025
What this trial tests

NA trial testing Selective tibial nerve block in Analgesia in 80 participants. Completed in 14 July 2025.

Timeline
1 May 2022
Primary endpoint
14 November 2024
14 July 2025

Quick facts

Lead sponsorCentre Hospitalier Universitaire Vaudois
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment80
Start date1 May 2022
Primary completion14 November 2024
Estimated completion14 July 2025
Sites1 location across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire Vaudois

Who can join

18 and older, any sex, with Analgesia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to compare the analgesic efficacy of the combination of an adductor canal and selective tibial nerve blocks versus adductor canal block and IPACK after ACL reconstruction under general anaesthesia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Selective tibial nerve block

Trials testing the same drug.

Other recruiting trials for Analgesia

Currently open trials in the same condition.

Other Centre Hospitalier Universitaire Vaudois trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05303233.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing